Company news
Xinjiang Baihuacun Pharam Tech Co. Ltd. Class A (SSE:600721) news
Xinjiang Baihuacun Pharam Tech Co. Ltd. Class A news releases on 6ix. Latest, Sep 25, 2026: "XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement…
Press releases & updates
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement on Completion of the Industrial and Commercial Registration Change and Issuance of a New Business License
September 24, 2026
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement on Appointment of Board Secretary
September 10, 2026
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
September 9, 2026
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Continuous Supervision Opinion for Q2 2026 of GUOTAI HAITONG SECURITIES CO., LTD. on the Detailed Report on Change in Equity Interests of XINJIANG BAI HUA CUN PHARMA TECH CO., LTD.
September 4, 2026
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement on Shareholding Reduction Plan of Shareholder
August 28, 2026
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 27, 2026
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement on Resolutions of the 12th Meeting of the 9th Board of Directors
August 24, 2026
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement on Severe Abnormal Fluctuations in Stock Trading and Risk Warning
August 12, 2026
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement on Risk Warning in Stock Trading
August 6, 2026
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading
July 16, 2026
"XINJIANG BAI HUA CUN PHARMA TECH CO., LTD."Announcement on Reply to the Shanghai Stock Exchange's Information Disclosure Supervisory Inquiry Letter on the Company's 2025 Annual Report
July 7, 2026
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Xinjiang Jurisdiction
June 17, 2026
Announcement on the Completion of Share Transfer Registration Under the Equity Transfer Agreement by the Controlling Shareholder and Actual Controller and the Progress of Change in Control
June 9, 2026
Announcement on Progress in Proposed Changes in Control Rights Passing the Compliance Audit of Shanghai Stock Exchange and Proposed Changes in Control Rights
June 5, 2026
Announcement on Adjusting Transfer Price in the Agreement-based Share Transfer by the Controlling Shareholder and Actual Controller
May 12, 2026
Announcement on Convening Performance and Cash Dividend Meeting for 2025 and Q1 2026
April 29, 2026
Announcement on Implementation of Dividend Distribution for 2025
April 28, 2026
Report for Q1 2026
April 24, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 17, 2026
Announcement on Progress in Wholly-owned Subsidiary Accepting Nantong Qinzhijian Teng Venture Capital Fund Shares and Outward Investment
April 10, 2026
Announcement on Progress in the Plan for a Change in Control and Trading Resumption
April 7, 2026
Announcement on Continued Trading Suspension Regarding the Planning of Change in Control Rights
April 1, 2026
Announcement on Progress in a Wholly-owned Subsidiary’s Participation in Nanjing Longmen New Medical Venture Capital Fund
March 27, 2026
Announcement on Wholly-owned Sub-subsidiary Obtaining High-tech Enterprise Certificate
February 4, 2026
Announcement on Abnormal Fluctuations in Stock Trading
January 9, 2026
Announcement on Termination of the Plan for a Change in Control and Trading Resumption
January 6, 2026
Announcement on Trading Suspension Regarding the Planning of Change in Control Rights
December 26, 2025
Announcement on Appointment of Rotating General Manager
December 19, 2025
Announcement on the Expiration and Termination of the Controlling Shareholder, Actual Controller, and Persons Acting in Concert
December 2, 2025
Announcement on Notifying Creditors of Offsetting Losses with Capital Reserve
November 12, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 31, 2025
Announcement on Resolutions of the 8th Meeting of the 9th Board of Directors
October 27, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 8, 2025
Announcement on Completing Cancellation of Stock Options in the 2021 Stock Option Incentive Plan
August 29, 2025
Announcement on Exercise Results and Changes in Shares of 2021 Stock Option Incentive Plan
August 21, 2025
Announcement on Resignation of Directors
July 18, 2025
Announcement on Exercise Results and Changes in Shares of 2021 Stock Option Incentive Plan in Q2 2025
July 2, 2025
Announcement on Attending Online Collective Reception Day for Investors of Listed Companies in Xinjiang Jurisdiction in 2025
May 15, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
April 29, 2025
Report for Q1 2025
April 25, 2025
Announcement on Progress of Wholly-owned Subsidiary Accepting New Medical Venture Capital Fund Shares and Outward Investment
April 24, 2025
Indicative Announcement on the Restricted Exercise Period of the 2021 Stock Option Incentive Plan
April 7, 2025
Announcement on Resolutions of the 2024 Annual General Meeting
April 2, 2025
Announcement on Exercise Results and Changes in Shares of 2021 Stock Option Incentive Plan in Q1 2025
April 1, 2025
Announcement on Provision of Online Voting Reminder Service for General Meeting
March 25, 2025
Announcement on Proposing to Use Self-owned Funds for Investment and Financial Management
March 11, 2025
Announcement on Wholly-owned Subsidiary Accepting New Medical Venture Capital Fund Shares and Outward Investment
February 26, 2025
Announcement on Wholly-owned Subsidiary Obtaining High-tech Enterprise Certificate
February 11, 2025
Announcement on Expected Increase in Annual Performance for 2024
January 20, 2025
Announcement on Progress of Wholly-owned Subsidiary's Participation in Investment in Pharmaceutical Industry Development Fund
January 13, 2025